Susvimo, a refillable ranibizumab implant for neovascular age-related macular degeneration, could reduce treatment burden by replacing monthly injections with 24-week refills. Medscape Medical News
Tag: News Alert
SMC Accepts First Drug to Improve Survival in Uveal Melanoma
Scotland approves tebentafusp for metastatic uveal melanoma, a rare eye cancer with a median survival of around 12 months. Medscape News UK
Europe Moves Closer to New Retinal Disease Biosimilar
A new anti-VEGF biosimilar has moved closer to European approval for several vision-threatening retinal diseases, including choroidal neovascularization. Medscape News Europe
FDA Approves First Dual-Agent Eye Drop for Presbyopia
The FDA has approved the first dual-agent eye drop to treat presbyopia, a condition that causes gradual loss of near vision in adults. Medscape Medical News
Biosimilars for Retina and Inflammatory Disease Get EMA Nod
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs. Medscape News Europe
Biosimilars for Retina and Inflammatory Disease Get EMA Nod
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs. Medscape News Europe
Rare Eye Disease Gets First NHS Drug Recommendation
NICE’s recommendation of idebenone (Raxone) for Leber hereditary optic neuropathy offers hope for patients against visual impairment. Medscape News UK
FDA Approves VIZZ Eye Drops to Treat Presbyopia
The effects of once-daily acelidine-based treatment last for up to 10 hours. Medscape Medical News
FDA Approves of VIZZ Eye Drops to Treat Presbyopia
The effects of once-daily acelidine-based treatment last for up to 10 hours. Medscape Medical News
MHRA Approves First UK Treatment for Thyroid Eye Disease
The Medicines and Healthcare products Regulatory Agency has approved teprotumumab, the first treatment to be licensed in the UK for adults with thyroid eye disease. Medscape News UK
FDA Okays Upadacitinib for Giant Cell Arteritis
This is the first and only oral JAK inhibitor indicated for giant cell arteritis, according to the manufacturer AbbVie. Medscape Medical News
FDA Approves First and Only Therapy for IgG4-RD
The CD19+ B-Cell targeted therapy reduced flare risk by 87% in a phase 3 clinical trial. Medscape Medical News
EMA Recommends Ryjunea for Pediatric Myopia
The atropine-based eye drop is designed to slow myopia progression in children. Medscape Medical News
Two New Drugs Approved for Age-Related Macular Degeneration
The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its refusal of marketing authorization for Syfovre. Medscape Medical News
New Drugs Turned Down by EU Safety Assessor
Drugs for ALS, age-related macular degeneration, and Duchenne muscular dystrophy did not get the green light due to lack of evidence. Medscape Medical News
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation. Medscape Medical News
FDA OKs High Concentration of Adalimumab Biosimilar Cyltezo
Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation. Medscape Medical News
CDC Investigating Reactions Linked to Counterfeit ‘Botox’
Reactions have included blurry vision, double vision, drooping eyelids, difficult swallowing or breathing, and other symptoms of botulism. MDedge News
FDA OKs Ninth Humira Biosimilar, With Interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month. Medscape Medical News
FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness
"The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade." FDA Approvals